Loxo Oncology Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
96
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.92B
Loxo Oncology General Information
Description
Operator of a biopharmaceutical company intended to serve people affected by cancer. The company specializes in developing oncology medicines that unequivocally show early signs of clinical activity and curate a balanced pipeline of medicines with the potential to treat cancer with dramatic effect.
Contact Information
Website
www.loxooncology.com(Operating Subsidiary)
Corporate Office
- 281 Tresser Boulevard
- 9th Floor
- Stamford, CT 06901
- United States
Corporate Office
- 281 Tresser Boulevard
- 9th Floor
- Stamford, CT 06901
- United States
Loxo Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 15-Feb-2019 | $6.92B | Completed | Generating Revenue | ||
| 10. PIPE | 30-Sep-2018 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Open Market | 31-Mar-2018 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 31-Mar-2017 | Completed | Generating Revenue | |||
| 7. PIPE | 05-Jan-2017 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Open Market | 31-Mar-2016 | Completed | Generating Revenue | |||
| 5. 2PO | 17-Nov-2015 | Completed | Generating Revenue | |||
| 4. IPO | 01-Aug-2014 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 06-May-2014 | $23.9M | $56.9M | Completed | Startup | |
| 2. Early Stage VC (Series A) | 03-Oct-2013 | $33M | $33M | Completed | Startup |
Loxo Oncology Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A1 | ||||||||
| Series A | 3,300,000 | $0.000100 | 8% | $10 | $10 | 44.13% |
Loxo Oncology Comparisons
Industry
Financing
Details
Loxo Oncology Competitors (68)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Olema Oncology | Formerly VC-backed | San Francisco, CA | ||||
| Monopar Therapeutics | Formerly VC-backed | Wilmette, IL | ||||
| CytImmune Sciences | Private Equity-Backed | Rockville, MD | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA |
Loxo Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Loxo Oncology Patents
Loxo Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230183266-A1 | Crystalline forms of ret inhibitor and preparation thereof | Pending | 13-Dec-2021 | ||
| AU-2022416156-A1 | Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor | Pending | 13-Dec-2021 | ||
| CA-3238202-A1 | Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor | Pending | 13-Dec-2021 | ||
| CA-3217452-A1 | Cocrystalline forms of a bruton's tyrosine kinase inhibitor | Pending | 14-May-2021 | ||
| AU-2022274771-A1 | Cocrystalline forms of a bruton's tyrosine kinase inhibitor | Pending | 14-May-2021 | A61K31/415 |
Loxo Oncology Executive Team (21)
| Name | Title | Board Seat |
|---|---|---|
| Jacob Van Naarden | Chief Executive Officer | |
| Nisha Nanda Ph.D | Chief Development Officer | |
| Winselow Tucker | Senior Vice President & Chief Commercial Officer, Oncology | |
| Ben Park Ph.D | Scientific Advisor | |
| David Solit MD | Scientific Advisor |
Loxo Oncology Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| David Bonita MD | OrbiMed | Board Member | |
| Keith Flaherty MD | Self | Board Member & Chairman, Scientific Advisory Board | |
| Steven Harr MD | Self | Board Member |
Loxo Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Loxo Oncology Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Aquilo Capital Management | Hedge Fund | Minority | ||
| Array BioPharma | Corporation | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
Loxo Oncology Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Redx Pharma (BTK inhibitor drug development program) | 28-Jul-2017 | Buildings and Property |
Loxo Oncology FAQs
-
When was Loxo Oncology founded?
Loxo Oncology was founded in 2013.
-
Who is the founder of Loxo Oncology?
Joshua Bilenker MD is the founder of Loxo Oncology.
-
Who is the CEO of Loxo Oncology?
Jacob Van Naarden is the CEO of Loxo Oncology.
-
Where is Loxo Oncology headquartered?
Loxo Oncology is headquartered in Stamford, CT.
-
What is the size of Loxo Oncology?
Loxo Oncology has 96 total employees.
-
What industry is Loxo Oncology in?
Loxo Oncology’s primary industry is Biotechnology.
-
Is Loxo Oncology a private or public company?
Loxo Oncology is a Private company.
-
What is the current valuation of Loxo Oncology?
The current valuation of Loxo Oncology is .
-
What is Loxo Oncology’s current revenue?
The current revenue for Loxo Oncology is .
-
How much funding has Loxo Oncology raised over time?
Loxo Oncology has raised $224M.
-
Who are Loxo Oncology’s investors?
Aisling Capital, Aquilo Capital Management, Array BioPharma, Deerfield Management, and Foresite Capital are 5 of 8 investors who have invested in Loxo Oncology.
-
Who are Loxo Oncology’s competitors?
Agios Pharmaceuticals, Olema Oncology, Monopar Therapeutics, CytImmune Sciences, and Vertex Pharmaceuticals are some of the 68 competitors of Loxo Oncology.
-
When was Loxo Oncology acquired?
Loxo Oncology was acquired on 15-Feb-2019.
-
Who acquired Loxo Oncology?
Loxo Oncology was acquired by Eli Lilly and Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
